Are you or someone you know living with focal epilepsy that isn’t responding to medications? We invite you to join our clinical study to explore a new, non-invasive treatment option using transcranial direct current stimulation (tDCS). Our goal is to investigate whether tDCS therapy can potentially help reduce the frequency and severity of seizures, providing hope for those with drug-resistant focal epilepsy.
Why This Study Matters
For many individuals with focal epilepsy, current treatment options don’t provide adequate control of seizures. This investigational study is designed to test tDCS, a safe and painless therapy that uses low electrical currents to stimulate targeted areas of the brain. Your participation can contribute to advancing research and potentially provide relief for many living with this condition.
You may qualify for this study if:
- You are 9 years old or older
- You have been diagnosed with focal epilepsy that is not responding to seizure medications
.png)
All study-related treatments and assessments are provided at no charge.
Compensation is available for your time, travel, and related expenses such as transportation, meals, or accommodations.
You won’t need to change or stop any existing epilepsy treatments.
You’ll be carefully monitored by medical professionals throughout the study to ensure your safety.
tDCS (transcranial direct current stimulation) is a non-surgical, non-invasive technique that delivers low-level electrical currents to specific areas of the brain through electrodes placed on the scalp. These currents aim to modulate brain activity in regions associated with epilepsy.
The seizure diary helps track your seizure activity before, during, and after treatment, allowing researchers to accurately assess the therapy’s effectiveness.
After completing the main trial, participants can opt into the OLE phase, where all eligible participants receive active tDCS treatment for 10 additional sessions followed by further monitoring. This phase allows participants to access the treatment beyond the initial randomized phase.
Eligibility will be determined through a brief screening process. If you meet the basic criteria (age 9+, diagnosis of focal epilepsy not controlled by medication), our team will guide you through the next steps.
